Tailoring Systemic Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Evidence by Disease Volume and Timing of Metastasis
Highlights
- Triplet therapy with ARPI + Docetaxel + ADT significantly improves overall survival in synchronous high-volume mHSPC compared with doublets.
- ARPI + ADT doublet therapy offers the greatest benefit in low-volume and metachronous cases compared to ADT alone.
- Docetaxel doublet has no added benefit when ARPI is available and feasible.
- Evidence integrated from 11 high-quality phase 3 trials, evaluated with a living network meta-analysis framework.
Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.